Bacterial Resistance to Antibiotics : From Molecules to Man

AN AUTHORITATIVE SURVEY OF CURRENT RESEARCH INTO CLINICALLY USEFUL CONVENTIONAL AND NONCONVENTIONAL ANTIBIOTIC THERAPEUTICS Pharmaceutically-active antibiotics revolutionized the treatment of infectious diseases, leading to decreased mortality and increased life expectancy. However, recent years have seen an alarming rise in the number and frequency of antibiotic-resistant "Superbugs." The Centers for Disease Control and Prevention (CDC) estimates that over two million antibiotic-resistant infections occur in the United States annually, resulting in approximately 23,000 deaths. Despite the danger to public health, a minimal number of new antibiotic drugs are currently in development or in clinical trials by major pharmaceutical companies. To prevent reverting back to the pre-antibiotic era when diseases caused by parasites or infections were virtually untreatable and frequently resulted in death new and innovative approaches are needed to combat the increasing resistance of pathogenic bacteria to antibiotics

for medical practitioners, researchers, academics, and professionals in public health, pharmaceuticals, microbiology, and related fields. [Publisher's Text]

686385 characters.